Scientech Research LLC Buys New Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Scientech Research LLC acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 140,295 shares of the company's stock, valued at approximately $1,052,000. Scientech Research LLC owned approximately 0.06% of Recursion Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in RXRX. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter valued at approximately $26,000. GAMMA Investing LLC increased its stake in Recursion Pharmaceuticals by 1,588.4% in the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company's stock valued at $48,000 after buying an additional 6,036 shares during the period. Amalgamated Bank increased its stake in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company's stock valued at $54,000 after buying an additional 2,459 shares during the period. Midwest Financial Group LLC purchased a new position in Recursion Pharmaceuticals during the 2nd quarter worth $90,000. Finally, Xponance Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter worth $98,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on RXRX shares. Needham & Company LLC cut their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a "buy" rating for the company in a report on Wednesday, September 4th. KeyCorp reduced their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating for the company in a report on Thursday, July 11th. Jefferies Financial Group dropped their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a report on Tuesday, September 3rd. Finally, Leerink Partners reduced their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a report on Tuesday, September 3rd. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $9.40.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX traded down $0.19 during mid-day trading on Friday, hitting $6.98. The stock had a trading volume of 3,615,037 shares, compared to its average volume of 4,818,485. The company has a 50 day simple moving average of $7.03 and a 200 day simple moving average of $8.21. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.96 billion, a price-to-earnings ratio of -4.36 and a beta of 0.82. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.97 and a 52-week high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The firm had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The company's quarterly revenue was up 30.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.38) EPS. Equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Christopher Gibson sold 20,000 shares of the company's stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total value of $120,800.00. Following the sale, the chief executive officer now owns 762,656 shares of the company's stock, valued at approximately $4,606,442.24. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the sale, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,606,442.24. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the business's stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $6.84, for a total transaction of $78,297.48. Following the completion of the transaction, the director now directly owns 7,109,875 shares of the company's stock, valued at approximately $48,631,545. The disclosure for this sale can be found here. Over the last quarter, insiders sold 225,682 shares of company stock worth $1,590,044. Insiders own 15.75% of the company's stock.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.